Abuse-Deterrent Opioids-Evaluation and Labeling
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 2, 2015
February 17, 2022
cd0f4ddf-e4fc-4694-a929-33733fb8e8db
Related Documents
Orally Disintegrating Tablets: Guidance for Industry
Guidance DocumentDecember 16, 2008Center for Drug Evaluation and Research
Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications
Guidance DocumentMay 6, 2011Center for Drug Evaluation and Research
ANDAs: Impurities in Drug Products: Guidance for Industry
Guidance DocumentNovember 29, 2010Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.